Crigler Najjar Syndrome, also called hyperbilirubinemia, is a chronic condition characterized by high levels of unconjugated bilirubin in the blood. The disease manifests as Jaundice at birth, and can progressively lead to kernicterus, a condition in which the accumulation of unconjugated bilirubin can damage brain...
Foamix Pharmaceuticals (NASDAQ: FOMX), a clinical stage biotechnology company that is focused on creating solutions for the unmet needs in dermatology by developing topical therapies, has announced that it has secured nearly $64 million in financing from Perceptive Advisors and OrbiMed. According to a company...
Cannabix Technologies (OTCPK: BLOZF), a pioneer in the development of Marijuana and other drug-testing devices, announced that its scientific team has developed a proprietary method that can detect the highest levels of ∆9-tetrahydrocannabinol (“THC”) from human breath till date. The company manufactures Cannabix Marijuana Breathalyzer...
Neuronal Ceroid Lipofuscinosis (NCL), or more commonly known as Batten disease, is a group of rare lysosomal storage disorders attributed to the dysfunction in the autosomal recessive gene, which causes mutations that hinder efficient cell functioning. They disrupt the cell’s natural waste disposal mechanism leading...
Opiant Pharmaceuticals, (NASDAQ: OPNT), which develops pharmacological solutions for addictions, disorders and substance abuse, announced that it has entered into an agreement with Sanofi (NYSE: SNY) to manufacture Opiant’s investigational agent OPNTOO4 (drinabant) for the treatment of Acute Cannabinoid Overdose (ACO). Drinabant, a selective CB1...
Puma Biotechnology (NASDAQ: PBYI), a biopharmaceutical company focused on Oncology, announced the submission of a supplemental New Drug Application (sNDA) to the FDA, for neratinib in combination with capecitabine for treatment of HER2-positive metastatic breast cancer in patients who have failed two or more prior...
BioXcel Therapeutics (NASDAQ: BTAI) is buoyed by the positive results from a Phase 1b clinical trial, to test the efficacy of BXCL501, its lead drug candidate for the treatment of agitation in patients suffering from Schizophrenia. The drug candidate was granted a fast track designation...
July 23, 2019 07:00 ET | Source: Bioxytran Inc. BOSTON, MASSACHUSETTS, July 23, 2019 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (OTC: BIXT), a developmental stage biotechnology company developing a pipeline of anti-necrosis drugs designed to treat hypoxia by delivering a small molecule carrying oxygen to the brain...
Tapinator Inc, (OTCQB: TAPM) a developer of category leading apps for mobile platforms which has built a library of more than 300 titles with more than 450 million mobile downloads, has announced plans to launch a new social casino game to be introduced in Q4,...
IntriCon Corporation (NASDAQ: IIN), a developer, manufacturer and distributor of miniature body-worn devices in the hearing healthcare and medical biotelemetry field, has secured a four-year Supply Agreement with Medtronic (NYSE: MDT), one of its largest customers. Medtronic is the market leader in Continuous Glucose Monitoring...
